Biocartis
PrivateLast Round
Recap
Nov 22, 2023
Est. Valuation
$490.7M
Total Funding Raised
$344.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Biocartis is a molecular diagnostics company that provides a fully automated, sample-to-result, real-time PCR platform for oncology and infectious disease testing.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine, Biotech Equipment
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biocartis Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Biocartis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Recap | Nov 22, 2023 | ||||
| Debt | Nov 22, 2023 | ||||
| Private Placement | Nov 29, 2022 | ||||
| Private Placement | Jan 23, 2019 | ||||
| IPO Announced | Apr 27, 2015 | ||||
Private Placement | Sep 4, 2014 |
Key People
Founding team and executive leadership
Biocartis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UBS Group AG | IPO |
| Korys | Series C, Series D |
| KBC Group N.V. | Debt |
| Advent Venture Partners | Series A, Series B |
| KBC Securities | Private Placement |
| Aescap | Series B |
| PMV | Private Placement, Series C, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2026
Developing a rapid breast cancer gene signature test with Medical College of Wisconsin.
- Mar 24, 2026
Partnering with Medical College of Wisconsin on breast cancer test development.
Biocartis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Biocartis's valuation, stock price, and market status.